N-MOmentum - study design for a placebo-controlled study of MEDI-551 in neuromyelitis optica

被引：0

作者：

Cree, B. A. C. ^{[1
]}

Bennett, J. L. ^{[2
]}

Hartung, H. -P. ^{[3
]}

Aktas, O. ^{[3
]}

Kim, H. J. ^{[4
,5
]}

Paul, F. ^{[6
]}

Pittock, S. ^{[7
]}

Weinshenker, B. ^{[7
]}

Wingerchuk, D. ^{[8
]}

Marignier, R. ^{[9
]}

Fujihara, K. ^{[10
]}

Cutter, G. ^{[11
]}

Flor, A. ^{[12
]}

Barron, G. ^{[13
]}

Patra, K. ^{[12
]}

Madani, S. ^{[12
]}

Katz, E. ^{[13
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Univ Colorado, Denver, CO 80202 USA

[3] Univ Dusseldorf, Dusseldorf, Germany

[4] Res Inst, Seoul, South Korea

[5] Natl Canc Ctr Hosp, Seoul, South Korea

[6] Charite, D-13353 Berlin, Germany

[7] Mayo Clin, Rochester, MN USA

[8] Mayo Clin, Scottsdale, AZ USA

[9] Lyon Univ Hosp, Lyon, France

[10] Tohoku Univ, Sendai, Miyagi 980, Japan

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] MedImmune, Gaithersburg, MD USA

[13] MedImmune, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1349

引用

页码：705 / 706

页数：2

共 50 条

[21] Long term efficacy outcomes with inebilizumab treatment in neuromyelitis optica spectrum disorder: the N-MOmentum trial
Cree, B.
Bennett, J.
Weinshenker, B.
Wingerchuk, D.
Paul, F.
Kim, H.
Pittock, S.
Fujihara, K.
Cutter, G.
Marignier, R.
Aktas, O.
Hartung, H.
Green, A.
Drappa, J.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J.
Katz, E.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 177 - 177
[22] Extent of B-cell depletion is associated with disease activity reduction in neuromyelitis optica spectrum disorder: results from the N-MOmentum study
Bennett, J. L.
Aktas, O.
Smith, M.
Rees, W. A.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 151 - 152
[23] Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension
Cree, B. A. C.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H-P.
Lublin, F.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
NEUROLOGY, 2020, 94 (15)
[24] Efficacy and Safety of Inebilizumab Among Non-White Demographic Groups with Neuromyelitis Optica Spectrum Disorder: N-MOmentum Study Subgroup Analysis
Paul, Friedemann
Fujihara, Kazuo
Avila, Mirla
Arakaki, Edson
Wu, Yanping
Patterson, Kristina R.
Cimbora, Dan
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 423 - 424
[25] The N-MOmentum Trial Of Inebilizumab For Neuromyelitis Optica Spectrum Disorder: Randomized Controlled Period And Long-term Open-label Extension
Cree, B. A.
Bennett, J. L.
Kim, H.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H.
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 10 - 11
[26] Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Weinshenker, Brian G.
Wingerchuk, Dean M.
Green, Ari J.
Bennett, Jeffrey L.
Kim, Ho Jin
Pittock, Sean J.
Fujihara, Kazuo
Paul, Friedemann
Cutter, Gary
Marignier, Romain
Aktas, Orhan
Hartung, Hans-Peter
She, Dewei
Smith, Michael
Rees, William
Patterson, Kristina
Cimbora, Daniel
Katz, Eliezer
Cree, Bruce A. C.
N MOmentum Study Investigators
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (08) : 945 - 955
[27] Inebilizumab Reduces the Risk of Disability Progression in Neuromyelitis Optica Spectrum Disorder: Outcomes From the N-MOmentum Trial
Fujihara, K.
Marignier, R.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Paul, F.
Cutter, G.
Green, A.
Aktas, O.
Hartung, H-P
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP82 - NP83
[28] Characterization of B-cell Subset Changes Following Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) With Inebilizumab: Results From the N-MOmentum study
Kim, H. J.
Bennett, J. L.
Aktas, O.
Rees, W. A.
Smith, M. A.
Del Nagro, C. J.
Yan, L.
Drappa, J.
Barron, G.
Ratchford, J. N.
She, D.
Cimbora, D.
Pittock, S.
Weinshenker, B. G.
Paul, F.
Marignier, R.
Wingerchuk, D.
Cutter, G.
Green, A.
Hartung, H-P
Katz, E.
Fujihara, K.
Levy, M.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP83 - NP84
[29] Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
Bennett, Jeffrey L.
Aktas, Orhan
Rees, William A.
Smith, Michael A.
Gunsior, Michele
Yan, Li
She, Dewei
Cimbora, Daniel
Pittock, Sean J.
Weinshenker, Brian G.
Paul, Friedemann
Marignier, Romain
Wingerchuk, Dean
Cutter, Gary
Green, Ari
Hartung, Hans-Peter
Kim, Ho Jin
Fujihara, Kazuo
Levy, Michael
Katz, Eliezer
Cree, Bruce A. C.
N-MOmentum Study Investigator
EBIOMEDICINE, 2022, 86
[30] Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
Cree, Bruce A. C.
Kim, Ho Jin
Weinshenker, Brian G.
Pittock, Sean J.
Wingerchuk, Dean M.
Fujihara, Kazuo
Paul, Friedemann
Cutter, Gary R.
Marignier, Romain
Green, Ari J.
Aktas, Orhan
Hartung, Hans -Peter
She, Dewei
Rees, William
Smith, Michael
Cimbora, Daniel
Katz, Eliezer
Bennett, Jeffrey L.
LANCET NEUROLOGY, 2024, 23 (06): : 588 - 602

← 1 2 3 4 5 →